Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns

I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating. In my view, the recent pullback in stock price seems primarily driven by the failure of Ionis/AstraZeneca's

I initiate coverage of Alnylam Pharmaceuticals ( ALNY ) with a non-consensus BUY rating . In my view, the recent pullback in stock price seems primarily driven by the failure of Ionis/AstraZeneca's